<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02707887</url>
  </required_header>
  <id_info>
    <org_study_id>15-0815</org_study_id>
    <secondary_id>R01DA026424</secondary_id>
    <nct_id>NCT02707887</nct_id>
  </id_info>
  <brief_title>Technology Enhanced Behavioral Activation Treatment for Substance Use</brief_title>
  <official_title>Technology Enhanced Behavioral Activation Treatment for Substance Use</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to:

        1. determine if a smartphone enhanced treatment for LETS ACT (LETS ACT-SE) is associated
           with increased long term treatment engagement, and in turn, improved long term treatment
           outcomes, and

        2. use functional magnetic resonance imaging (fMRI) to identify the effects of LETS ACT-SE
           on the neuromarkers of reward sensitivity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Comorbid substance use disorder (SUD) and depression is highly prevalent and associated with
      elevated rates of post treatment relapse to substance use, HIV risk behavior, and associated
      poor mental and physical health outcomes. Further, rates of substance use and depression
      disproportionately affect minority groups and those living in poverty. Although efficacious,
      the often complex, specialized nature of CBT poses problems in its integration into substance
      use treatment programs. Budget cuts for mental health and substance use treatment both
      nationally and in the state of North Carolina, reduce availability of publically funded
      treatment programs and staff to patient ratios. To address this limitation, a behavioral
      activation (BA) treatment, the Life Enhancement Treatment for Substance Use (LETS ACT), was
      developed to treat depressive symptoms among a predominantly African American sample of low
      income illicit drug users currently receiving residential substance use treatment.
      Collectively, two Stage I studies and 1 year follow-up data from the investigators Stage II
      R01DA026424 indicate that compared to a control condition, LETS ACT is associated with
      significantly better outcomes for treatment retention, post treatment abstinence, HIV sexual
      risk behavior, depressive symptoms, and environmental reward.

      Although these strong outcomes suggest that LETS ACT may be ready for a Stage III
      dissemination trial, it is of note that there was a significant indirect effect of LETS ACT
      homework compliance on post treatment substance use and HIV sexual risk behavior via the
      theoretically proposed BA mechanism of action, environmental reward. In the context of
      limited access to care, these findings point to the need to identify cost-effective
      delivery-vehicles to increase treatment engagement outside of clinician sessions. Further,
      identifying neuroscience based biomarkers (neuromarkers) underlying key theoretical aspects
      of BA (i.e., reward sensitivity), and their relation to heterogeneity in BA treatment
      response among substance users with depression, are critical for the identification of
      accurately targeted interventions.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Timeline Followback (TLFB)</measure>
    <time_frame>TLFB will be assessed from baseline to a 12-month follow up period.</time_frame>
    <description>The Time Line Follow Back is a self-report measure of drug and alcohol use.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Psychiatric Research Interview for Substance and Mental Disorders (PRISM-5)</measure>
    <time_frame>PRISM will be assessed from baseline to a 12-month follow up period.</time_frame>
    <description>The PRISM is a diagnostic interview with subscales that will be used to screen for psychosis and assess lifetime and current DSM-5 Axis-I psychopathology</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Form Health Survey (SF-12)</measure>
    <time_frame>SF-12 will be assessed from baseline to a 12-month follow up period.</time_frame>
    <description>The SF-12 is a 12-item self-report measure of mental and physical health-related functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Behavioral Activation for Depression Scale (BADS)</measure>
    <time_frame>BADS will be assessed from baseline to a 12-month follow up period.</time_frame>
    <description>The BADS is a 25-item self-report measure of overall level of activity involvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily Goals Form</measure>
    <time_frame>Daily Goals Forms will be assessed on an ongoing basis between baseline to a 12-month follow up period.</time_frame>
    <description>The Daily Goals Form is used to measure Treatment Engagement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reward Probability Index (RPI)</measure>
    <time_frame>RPI will be assessed from baseline to a 12-month follow up period.</time_frame>
    <description>The RPI is a 20-item self-report measure used to assess environmental reward and punishment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Texas Christian University (TCU) HIV/AIDS Risk Assessment Form</measure>
    <time_frame>TCU will be assessed from baseline to a 12-month follow up period.</time_frame>
    <description>The TCU is a self-structured interview that measures HIV risk behavior in the domains of drug use and sex</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug Use History Questionnaire (DUQ)</measure>
    <time_frame>DUQ will be assessed once at baseline.</time_frame>
    <description>The DUQ is a 12-item self-report measure used to determine lifetime and past year substance use history.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinalysis</measure>
    <time_frame>Urinalysis is assessed from post treatment to a 12-month follow up period</time_frame>
    <description>Urinalysis is a biological measure of substance use.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Breathalyzer</measure>
    <time_frame>Breathalyzer will be assessed from baseline to a 12-month follow up period.</time_frame>
    <description>Breathalyzer is a biological measure of alcohol use.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beck Depression Inventory-II (BDI-II)</measure>
    <time_frame>BDI-II will be evaluated from baseline to a 12-month follow up period</time_frame>
    <description>The Beck Depression Inventory is a 21-item self-report measure of depressive symptoms</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Substance-Related Disorders</condition>
  <condition>Depressive Disorder</condition>
  <condition>Behavioral Symptoms</condition>
  <condition>Risk-Taking</condition>
  <condition>Sexual Behavior</condition>
  <arm_group>
    <arm_group_label>Treatment as Usual</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients are offered substance use group therapy including relapse prevention. They are also provided medical consultation on an ongoing basis as needed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LETS ACT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The Life Enhancement Treatment for Substance Use (LETS ACT) involves the discussion of the treatment rationale, identification of values and goals in various life areas and activities in line with chosen life areas, and training for patients to identify their cycle of negative mood and behavior using forms to track their daily goals.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LETS ACT-SE</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants assigned to the smartphone-enhanced LETS ACT (LETS ACT-SE) condition will be provided the exact same treatment as outlined in LETS ACT, except that LETS ACT-SE participants will record their daily goals using smartphone technology.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>LETS ACT</intervention_name>
    <description>The Life Enhancement Treatment for Substance Use (LETS ACT)</description>
    <arm_group_label>LETS ACT</arm_group_label>
    <other_name>Behavioral Activation</other_name>
    <other_name>Life Enhancement Treatment for Substance Use</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>LETS ACT-SE</intervention_name>
    <description>Participants assigned to the smartphone-enhanced LETS ACT (LETS ACT-SE) condition will be provided the exact same treatment as outlined in LETS ACT, except that LETS ACT-SE participants will record their daily goals using smartphone technology.</description>
    <arm_group_label>LETS ACT-SE</arm_group_label>
    <other_name>Behavioral Activation</other_name>
    <other_name>Smartphone-Enhanced LETS ACT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Treatment as Usual</intervention_name>
    <description>Participants will receive the treatment typically provided to patients at the substance use treatment facility.</description>
    <arm_group_label>Treatment as Usual</arm_group_label>
    <arm_group_label>LETS ACT</arm_group_label>
    <arm_group_label>LETS ACT-SE</arm_group_label>
    <other_name>TAU</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Between 18 and 55

          -  Meet criteria for DSM-V substance use disorder

          -  Elevated depressive symptoms (BDI â‰¥ 14)

        Exclusion Criteria:

          -  Limited mental competency (MMSE &lt; 23)

          -  Psychosis

          -  The use of psychotropic medication for &lt; 3 months

          -  The inability to give informed, voluntary, written consent to participate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stacey Daughters, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stacey B Daughters, Ph.D.</last_name>
    <phone>919-962-9925</phone>
    <email>daughter@unc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-3270</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacey B Daughters, Ph.D.</last_name>
      <phone>919-962-9924</phone>
      <email>daughter@unc.edu</email>
    </contact>
    <investigator>
      <last_name>Stacey B Daughters, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southlight Healthcare</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stacey Daughters</last_name>
      <email>daughter@unc.edu</email>
    </contact>
    <investigator>
      <last_name>Stacey B Daughters, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 27, 2015</study_first_submitted>
  <study_first_submitted_qc>March 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 14, 2016</study_first_posted>
  <last_update_submitted>September 14, 2017</last_update_submitted>
  <last_update_submitted_qc>September 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mental Disorders</keyword>
  <keyword>Mood Disorders</keyword>
  <keyword>Behavioral Activation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Substance-Related Disorders</mesh_term>
    <mesh_term>Behavioral Symptoms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

